Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778428 | 0.85 | PRMT6 (0.44) | PRMT6CYP2A6PDCD1CD274 | |
| SCHEMBL13744015 | 0.82 | HRH3 (0.59) | CYP2A6HRH3CYP11B1CYP11B2 | |
| SCHEMBL13778467 | 0.81 | AOC3 (0.44) | PRMT6CYP2A6LTA4HCD274CYP11B1 | |
| SCHEMBL13743490 | 0.78 | MKNK1 (0.53) | CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL13778459 | 0.78 | CYP11B1 (0.41) | PRMT6CYP11B1CYP11B2 | |
| SCHEMBL3670575 | 0.76 | LTA4H (0.38) | PRMT6CHEK1LTA4HS1PR1HRH3 | |
| SCHEMBL5028754 | 0.76 | PYCR1 (0.53) | PRMT6CHEK1SPHK1PRMT8PDCD1 | |
| SCHEMBL13743738 | 0.76 | HRH3 (0.61) | CYP2A6HRH3CYP11B1CYP11B2 | |
| SCHEMBL13778502 | 0.75 | CYP2A6 (0.37) | PRMT6CYP2A6S1PR1CYP11B1CYP11B2 | |
| SCHEMBL7662648 | 0.74 | HSD17B10 (0.41) | PRMT6CHEK1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | PRMT6 1956/4885CHEK1 2632/4885CYP2A6 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.